National Engineering Research Center for the Emergency Drug, Beijing Institute of Pharmacology and Toxicology, Beijing 100850, China.
Beijing Sunho Pharmaceutical Co., Ltd., Beijing 102600, China.
Viruses. 2024 Sep 14;16(9):1467. doi: 10.3390/v16091467.
Influenza viruses remain a major threat to human health. Four classes of drugs have been approved for the prevention and treatment of influenza infections. Oseltamivir, a neuraminidase inhibitor, is a first-line anti-influenza drug, and baloxavir is part of the newest generation of anti-influenza drugs that targets the viral polymerase. The emergence of drug resistance has reduced the efficacy of established antiviral drugs. Combination therapy is one of the options for controlling drug resistance and enhancing therapeutical efficacies. Here, we evaluate the antiviral effects of baloxavir combined with neuraminidase inhibitors (NAIs) against wild-type influenza viruses, as well as influenza viruses with drug-resistance mutations. The combination of baloxavir with NAIs led to significant synergistic effects; however, the combination of baloxavir with laninamivir failed to result in a synergistic effect on influenza B viruses. Considering the rapid emergence of drug resistance to baloxavir, we believe that these results will be beneficial for combined drug use against influenza.
流感病毒仍然是人类健康的主要威胁。目前已有四类药物被批准用于预防和治疗流感感染。奥司他韦是一种神经氨酸酶抑制剂，是一线抗流感药物，而巴洛沙韦则属于针对病毒聚合酶的最新一代抗流感药物。耐药性的出现降低了现有抗病毒药物的疗效。联合治疗是控制耐药性和提高治疗效果的选择之一。在这里，我们评估了巴洛沙韦联合神经氨酸酶抑制剂（NAIs）对野生型流感病毒以及具有耐药突变的流感病毒的抗病毒作用。巴洛沙韦与 NAIs 的联合使用产生了显著的协同作用；然而，巴洛沙韦与拉尼米韦的联合使用对乙型流感病毒没有产生协同作用。考虑到对巴洛沙韦迅速出现耐药性，我们认为这些结果将有助于联合使用药物来对抗流感。
